‘Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, market analysis suggests.
A 2025 report published by GlobalData, which analysed the seven major markets of the US, UK, France, Germany, Italy, Spain, and Japan, forecasts sector sales will reach the $22.4bn figure by 2033, up from $8.5bn in 2023, reflecting a compound annual growth rate (CAGR) of 10.2%. While not as fast-growing as the weight loss market in the metabolic disease space, the AD market growth is salient given the market's size compared to other dermatology indications.
GlobalData healthcare analyst, Filippos Maniatis, comments: 'AD is a growing market with an impressive pipeline of new products from current and future players in the field. The AD space was previously dominated by broad-acting immunomodulatory agents, which are now being slowly replaced by more targeted agents. This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents.'
GlobalData is the parent company of Pharmaceutical Technology.
One of those targeted agents that has taken the market by storm is Regeneron and Sanofi's jointly developed Dupixent (dupilumab), first approved in the US in 2017. The blockbuster monoclonal antibody has seen its sales increase year-over-year amid high uptake from AD – reaching $14.9bn in sales in 2024. Dupixent is approved for a range of diseases, including a lucrative asthma indication.
The report says that the gap of unmet need in AD, which is closing courtesy of Sanofi and Regeneron, is set to shrink even further depending on future approvals for more targeted therapies.
One modality poised as a future disruptor is the OX40 inhibitor class of drugs that work by inhibiting T-cell activation and inflammation via the OX40 receptor on the immune cells. Pipeline candidates in development include Amgen and Kyowa Kirin's rocatinlimab, Sanofi's amlitelimab, and Astria Therapeutics' telazrolimab.
Another class with a potential future in AD is interleukin (IL) inhibitors. LEO Pharma, GSK, and Nektar all have assets in clinical development.
Maniatis concludes: 'With multiple pipeline agents in development, key unmet needs may be further addressed. Such unmet needs include the lack of personalised treatments through improved diagnostic methods, the high cost of current therapy options, the limited therapeutic options for chronic hand eczema, and better long-term disease control and management.'
"'Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Art-eating fungus attacks Rome's ancient underground frescoes
A devastating infestation of microbugs is damaging the treasured underground frescoes that decorate the labyrinths of ancient catacombs beneath Rome. A vast network of tunnels, dug into the soft, porous tufa rock that underlies much of the city, was created in the early Christian era for the burial of the dead. They were also used as clandestine meeting places at a time when Christians were persecuted by Rome's emperors. But the colourful frescoes that adorn the ceilings and walls of the catacombs are being eaten away by microorganisms, a phenomenon that experts say is being accelerated by climate change. Rising temperatures have increased humidity levels inside the underground burial sites, encouraging the growth of bacteria, moss and fungus. The alarm about the rampant art-eating fungus has been raised by a Vatican department, the Pontifical Commission for Sacred Archaeology. 'The survival of frescoes which were created 2,000 years ago is at risk,' said Monsignor Pasquale Iacobone, the head of the department. 'There is an increase in the proliferation of vegetation and the damage is unprecedented. It's the effect of climate change and the increase in outside temperatures.' Ancient Romans, who cremated their dead, banned Christians from burying corpses within the walls of the capital. So the Christians instead dug underground passageways for the interment of their dead, eventually excavating around 300kms of tunnels beneath Rome. They wrapped the dead in shrouds and laid them to rest in rectangular niches that were carved out of the tunnel walls. Among the treasures under threat are striking frescoes in the San Callisto Catacomb, which mark some of the earliest surviving examples of Christian art. San Callisto, the biggest and most famous of Rome's catacombs, was established in the second century AD and contained the remains of about half a million people, as well as seven popes who were martyred in the third century AD. 'Along with the six catacombs that are open to the public, the problem is affecting all 400 of the decorated chambers that exist in Rome's 60 catacombs. We are seeing an unexpected increase in biological infestations,' Barbara Mazzei, an archaeologist and an expert on the catacombs, told Corriere della Sera newspaper. While the problem underground is high humidity, the issue above ground is a lack of moisture – high temperatures and drought conditions mean that trees are sinking their roots deeper, breaking through the ceilings of the catacombs and penetrating the frescoes. The confined, subterranean nature of catacombs and the lack of ventilation mean that it is hard for experts to use chemicals such as biocides to combat the growth of bacteria and mould. Instead, they are experimenting with natural products that are not harmful to humans, including essential oils made from lavender, thyme and cinnamon. The threats faced by the catacombs were revealed at a seminar in Rome organised by the International Institute for Conservation of Historic and Artistic Works. Many of the catacombs lie beneath the Appian Way, the 'regina viarum' or 'queen of roads' that once ran from Rome to the distant port of Brindisi on the Adriatic coast. In 2010, the earliest known icons of four of Christ's apostles were discovered on the ceiling of an elaborately decorated chamber in a catacomb beneath the streets of Rome. Scientists used advanced laser technology to remove a hardened crust of dirt and calcium deposits in order to bring to light the brightly coloured fourth century paintings of Saints John, Paul, Andrew and Peter. The images adorn the ceiling of a vault, carved out of volcanic rock, which provided the last resting place of a rich Roman noblewoman who converted to Christianity. Archaeologists also found an early image of Christ, a painting of a naked Daniel with lions at his feet and a sketch of Jesus raising Lazarus from the dead. The catacombs of Santa Tecla, a labyrinth of tunnels, galleries and burial chambers, lie hidden beneath a five-storey office in Ostiense, a residential area of Rome. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
19 hours ago
- Yahoo
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)'s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD treatment. This decline comes in contrast to a 2% rise in the broader market, suggesting that investors may be focusing on other company initiatives, such as SNY's recent partnership with Stagecoach Performing Arts to raise awareness about Type 1 diabetes. Despite the short-term drop, Sanofi (NASDAQ:SNY)'s long-term performance remains strong. Over the past five years, the company has delivered a total return of 19.59%, outpacing both the French Pharmaceuticals sector and the broader market, which saw declines of 4% and 4.5% respectively in the past year. Analysts remain optimistic about Sanofi (NASDAQ:SNY)'s future, with the current share price at €95.9 and a consensus target of €117.17, an 18.5% potential upside. The company's Projections for 2028 include revenues of €51.2 billion and earnings of €10.2 billion, supported by innovative drug development and efficient operations. While we acknowledge the potential of SNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
a day ago
- Yahoo
Chicken Salad Chick to open ten new restaurants in Minneapolis
US-based fast casual restaurant Chicken Salad Chick is broadening its footprint in the Midwest with ten new restaurants in the Minneapolis area. This is a significant step for the brand as it introduces its dining experience to the Upper Midwest. The Coffey family, with a basketball legacy, is behind the signed agreement that will bring the franchise to the region. Richard Coffey said: "We knew we wanted to go into business with a brand that we could all get behind. "Chicken Salad Chick stood out because of the support and communication we've received from the team. This is more than a business venture, it's a family journey, and we're excited to do it with a brand that feels the same way." The brand's strategic growth plan includes opening the ten locations before 2030, targeting development in Hennepin and Ramsey County. With an open real estate landscape, Chicken Salad Chick sees opportunities for market growth in the Midwest. Franchise development vice-president Mark Verges stated: "We're thrilled to have a passionate and community-driven family join Chicken Salad Chick. "Their deep roots in Minnesota and commitment to giving back make them great partners as we grow our presence in the Midwest." Chicken Salad Chick is leveraging the momentum from 2024, aiming to set new records with franchise deals across the US in 2025. The franchise development team has identified Illinois, Iowa, Michigan, Minnesota, Ohio, Pennsylvania, West Virginia and Wisconsin as key areas for growth. The brand has experienced a 13% increase in unit count year-on-year and reports more than $400m in system-wide sales, a 56% increase over 2021, with an average unit volume (AUV) of $1.48m, according to its 2024 franchise disclosure document (FDD). In addition to the Midwest expansion, Chicken Salad Chick recently announced plans to increase its presence in Texas with a new outlet in Temple. "Chicken Salad Chick to open ten new restaurants in Minneapolis" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
